The “Fast Money” traders discusses whether Donald Trump is a risk to his own market rally, as he continues to target different sectors with criticism.
Chris Retzler, Needham Small Cap Growth Fund, and Peter Andersen, Fiduciary Trust CIO, weigh in on the markets in light of President-elect Donald Trump's first news conference since Election Day.
The iShares Nasdaq Biotechnology ETF (IBB) briefly fell more than 2.5 percent, tracking for its first negative day of 2017.
Gilead CEO John Milligan made his comments on CNBC's "Fast Money" on Tuesday.
The "Fast Money" traders share their final trades of the day including Gilead and General Motors.
John Milligan, Gilead president and CEO, speaks to CNBC's Meg Tirrell about potential M&A, drug-pricing pressure under President-elect Donald Trump and the company's hepatitis C drugs.
The "Fast Money" traders weigh in on the health care sector, as the Trump administration attempts to repeal Obamacare.
The ruling for Mumia Abu-Jamal may lead to similar decisions in favor of other infected prisoners, which could strain prison budgets.
These are the stocks posting the largest moves after the bell.
"Fast Money Halftime Report" traders Jon and Pete Najarian give their best strategies for 2017 and give some top picks.
Jim Cramer rattles off his take on caller favorite stocks, including this company with little growth.
Jim Cramer drilled down on retail's woes and how the Trump administration could cause further pain to the retail cohort.
CNBC's Meg Tirrell looks at which stocks in the IBB of more than $1 billion market cap have the biggest potential upside.
These are the top picks of Causeway Capital Management's Sarah Ketterer and Needham Funds' Chris Retzler.
Donald Trump is likely to go after a short list of drug companies in his vow to bring prices down, says Jake Novak.
The pharmaceutical company wins its hepatitis C drug trial against Gilead Sciences.
Some of the names on the move ahead of the open.
Merck was awarded $2.54 billion in royalties by a jury in a patent lawsuit against Gilead Sciences over Gilead's hepatitis C drugs.
These are the stocks posting the largest moves after the bell, including Oracle, Agio Pharmaceuticals, Adobe and more.
Shares of Gilead sink after-hours following a court order to pay Merck $2.5 billion in Hepatitis C royalties. CNBC's Meg Tirrell reports. The "Fast Money" traders weigh in.